Evidence map›Paper›PMID 37832553›Full record

ArticleCancer cell2023

Co-op CARs for targeting acute myeloid leukemia.

Taisuke Kondo, Naomi Taylor

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Taisuke KondoPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: taisuke.kondo@nih.gov.
Naomi TaylorPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Université de Montpellier-IGMM, Montpellier, France. Electronic address: taylorn4@mail.nih.gov.
Institut de Génétique Moléculaire de Montpellier · FRNational Cancer Institute · US

Funding

Metabolic regulation of T cell effector function and anti-tumor immunotherapyZIABC011923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TAYLOR, NAOMI · 2019 to 2025
$9.5M
Intramural NIH HHS ZIA BC011923
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.

Indexed as

Leukemia, Myeloid, AcuteHumansImmunotherapy, Adoptive

Identifiers

PMID37832553
OpenAlexW4387570526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.